Your browser doesn't support javascript.
loading
Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study.
Urata, Tomohiro; Naoi, Yusuke; Jiang, Aixiang; Boyle, Merrill; Sunami, Kazutaka; Imai, Toshi; Nawa, Yuichiro; Hiramatsu, Yasushi; Yamamoto, Kazuhiko; Fujii, Soichiro; Yoshida, Isao; Yano, Tomofumi; Chijimatsu, Ryota; Murakami, Hiroyuki; Ikeuchi, Kazuhiro; Kobayashi, Hiroki; Tani, Katsuma; Ujiie, Hideki; Inoue, Hirofumi; Tomida, Shuta; Yamamoto, Akira; Kondo, Takumi; Fujiwara, Hideaki; Asada, Noboru; Nishimori, Hisakazu; Fujii, Keiko; Fujii, Nobuharu; Matsuoka, Ken-Ichi; Sawada, Keisuke; Momose, Shuji; Tamaru, Jun-Ichi; Nishikori, Asami; Sato, Yasuharu; Yoshino, Tadashi; Maeda, Yoshinobu; Scott, David W; Ennishi, Daisuke.
Afiliação
  • Urata T; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Naoi Y; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Jiang A; Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Boyle M; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Sunami K; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Imai T; Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Nawa Y; British Columbia Cancer, Centre for Lymphoid Cancer, Vancouver, BC, Canada.
  • Hiramatsu Y; British Columbia Cancer, Centre for Lymphoid Cancer, Vancouver, BC, Canada.
  • Yamamoto K; Department of Hematology, NHO Okayama Medical Center, Okayama, Japan.
  • Fujii S; Department of Hematology and Blood Transfusion, Kochi Health Sciences Center, Kochi, Japan.
  • Yoshida I; Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Yano T; Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan.
  • Chijimatsu R; Department of Hematology and Oncology, Okayama City Hospital, Okayama, Japan.
  • Murakami H; Department of Hematology, Japanese Red Cross Okayama Hospital, Okayama, Japan.
  • Ikeuchi K; Department of Hematologic Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan.
  • Kobayashi H; Department of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan.
  • Tani K; Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Ujiie H; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Inoue H; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Tomida S; Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Yamamoto A; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Kondo T; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Fujiwara H; Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Asada N; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Nishimori H; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Fujii K; Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Fujii N; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Matsuoka KI; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Sawada K; Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Momose S; Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Tamaru JI; Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama, Japan.
  • Nishikori A; Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Sato Y; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Yoshino T; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Maeda Y; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Scott DW; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Ennishi D; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Blood Adv ; 7(24): 7459-7470, 2023 12 26.
Article em En | MEDLINE | ID: mdl-37552496
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão